Clinical Study Of Essential Thrombocytosis

Objective: The aim of this study was to improve doctors' clinical abilities in the treatment of essential thrombocytosis(ET)that driven by mutations of JAK2,CALR and MPL genes,of which patients' laboratory and clinical characteristics were studied to provide reference data to clinical treatment and to estimate prognosis.Methods: The gene test,laboratory examinations and clinical data of ET patients were collected from the Department of Hematology,Ningxia Hui Autonomous Region People's Hospital from January 2014 to December 2019.According to the different gene mutation types,the patients were divided into JAK2 mutation group,MPL mutation group and CALR mutation group.To analyze the occurrence rate of JAK2,MPL and CALR gene mutation in BCR-ABL negative ET patients,and the laboratory and clinical characteristics in those patients' was analyzed as well.Results: The data of JAK2 mutation group and CALR mutation group showed that there was no significant difference in gender distribution,smoking and alcohol.There was no significant difference in the incidence of thrombotic events,hypertension,diabetes,hepatomegaly,dizziness,cyanosis,pruritus and bone pain between JAK2 and CALR mutation groups.The first diagnosis age,the incidence of splenomegaly and asthenia,and the average level of portal vein width,spleen thickness and pulmonary artery systolic blood pressure,white blood cell count,hemoglobin,lactate dehydrogenase,hypersensitive C-reactive protein and beta 2-microglobulin in JAK2 mutation group was significantly higher than that in CALR mutation group.On the contrary,the incidence of hyperhomocysteinemia and hyperlipidemia,the platelet count and blood homocysteine levels in CALR mutation group was higher than that in JAK2 mutation group.Conclusion: The average age at first dignosis of ET patients with JAK2 gene mutation was different from the patients with CALR gene mutation.There are differences in several clinical characteristics and laboratory characteristics in different gene mutation of ET patients,which may lead to differences in the probability of adverse events and prognosis during follow-up visit or treatment in the of different gene mutation groups,requiring further follow-up in clinical process.